LQDA Form 144: Multiple April 2026 Share Resales

Serendipity BioPharma LLC and related parties reported multiple resale transactions of restricted common stock of LQDA.

Rhea-AI Filing Summary

Serendipity BioPharma LLC and related parties reported multiple resale transactions of restricted common stock of LQDA. The excerpt lists sales including 04/16/2026 entries for 25,000 shares (proceeds $1,003,000.00) and earlier 10b5-1 sales on 04/15/2026 (25,000 shares, $1,003,522.50), 04/14/2026 (3,300 shares, $132,000.00), and other dated entries. The records identify Roger Jeffs as a reporting party for a 04/13/2026 sale of 32,744 shares (proceeds $1,256,387.28).

Insights

Securities Compliance Specialist

Form 144s list planned or completed resale of restricted shares under prescribed rules.

These entries document multiple 10b5-1 plan executions and individual resales for LQDA, with specific share counts and gross proceeds shown on dates in April 2026.

Timing and method (10b5-1) indicate pre-arranged dispositions; subsequent filings or broker confirmations may clarify settlement and net proceeds.

Corporate Counsel (Securities)

Transactions appear administrative and routine; disclosure supports resale compliance rather than new corporate actions.

The report names an entity and an individual, lists per‑trade shares and gross proceeds, and references NASDAQ as the market. Form 144 filings are procedural notices required when restricted/security holders intend to resell.

Watch for any related Form 4/5 or broker reports for final settlement details.

Key Figures

Sale — 04/16/2026: 25,000 shares Sale — 04/15/2026: 25,000 shares Sale — 04/14/2026: 3,300 shares +3 more

6 metrics

Sale — 04/16/2026 25,000 shares gross proceeds $1,003,000.00

Sale — 04/15/2026 25,000 shares gross proceeds $1,003,522.50

Sale — 04/14/2026 3,300 shares gross proceeds $132,000.00

Sale — 04/13/2026 (Roger Jeffs) 32,744 shares gross proceeds $1,256,387.28

Sale — 04/10/2026 21,433 shares gross proceeds $859,876.96

Sale — 04/09/2026 25,000 shares gross proceeds $1,002,887.50

Key Terms

Form 144, 10b5-1, restricted common stock

3 terms

Form 144 regulatory

"144: Securities To Be Sold ... 144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

10b5-1 regulatory

"10b5-1 Sales for SERENDIPITY BIOPHARMA LLC ... Common | 04/15/2026 | 25000"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

restricted common stock financial

"144: Securities To Be Sold ... Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does LQDA Form 144 filing show about recent share sales?

It shows several resale transactions totaling tens of thousands of shares in April 2026. The filing lists individual trades on 04/09/2026 through 04/16/2026, including multiple 10b5-1 plan sales and a reported sale by Roger Jeffs.

Were the April 2026 LQDA sales made under a 10b5-1 plan?

Yes; multiple entries are labeled as 10b5-1 sales in the excerpt. Specific 10b5-1 transactions include sales on 04/15/2026, 04/14/2026, 04/10/2026, and others shown.

How many shares did Roger Jeffs report selling in the LQDA filing?

Roger Jeffs is listed for a sale of 32,744 shares on 04/13/2026. The excerpt reports gross proceeds of $1,256,387.28 for that transaction.

What gross proceeds are reported for the 25,000‑share LQDA sale on 04/16/2026?

The excerpt lists gross proceeds of $1,003,000.00 for a 25,000‑share sale attributed to the reporting filer on 04/16/2026.

Does this Form 144 imply insider misconduct or unusual activity for LQDA?

No; the filing records planned or completed resales and multiple 10b5-1 entries. Form 144s are routine notices; the excerpt does not allege misconduct or irregular trading patterns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:13 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001231615
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIQUIDIA CORPORATION
SEC File Number	001-39724
Address of Issuer	419 Davis Drive, Suite 100, Morrisville NORTH CAROLINA 27560
Phone	9193284400
Name of Person for Whose Account the Securities are To Be Sold	SERENDIPITY BIOPHARMA LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	1003000.00	88114429	04/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2020	Merger or Acquisition	Issuer			25000	11/18/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/15/2026	25000	1003522.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/14/2026	3300	132000.00
ROGER JEFFS 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/13/2026	32744	1256387.28
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/10/2026	21433	859876.96
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/09/2026	25000	1002887.50

144: Remarks and Signature

Remarks
Date of Notice	04/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/05/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Roger Jeffs
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)